Jacklynn V. Egger

4.6k total citations · 1 hit paper
30 papers, 941 citations indexed

About

Jacklynn V. Egger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jacklynn V. Egger has authored 30 papers receiving a total of 941 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jacklynn V. Egger's work include Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Jacklynn V. Egger is often cited by papers focused on Lung Cancer Research Studies (11 papers), Lung Cancer Treatments and Mutations (11 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Jacklynn V. Egger collaborates with scholars based in United States, United Kingdom and Taiwan. Jacklynn V. Egger's co-authors include Charles M. Rudin, Jennifer L. Sauter, William D. Travis, Natasha Rekhtman, Amanda Beras, Matthew D. Hellmann, W. Victoria Lai, Triparna Sen, John T. Poirier and Achim A. Jungbluth and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jacklynn V. Egger

28 papers receiving 933 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization

2020 301 citations Marina K. Baine, Min‐Shu Hsieh et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jacklynn V. Egger United States	12	714	368	307	230	100	30	941
Hibiki Udagawa Japan	17	758 1.1×	528 1.4×	232 0.8×	428 1.9×	159 1.6×	80	1.1k
Alexander Augustyn United States	11	673 0.9×	295 0.8×	289 0.9×	566 2.5×	259 2.6×	25	1.1k
Yuki Matsumura Japan	18	487 0.7×	465 1.3×	186 0.6×	188 0.8×	222 2.2×	69	986
W. Victoria Lai United States	11	558 0.8×	171 0.5×	359 1.2×	200 0.9×	46 0.5×	24	669
Ilaria Maggio Italy	15	375 0.5×	222 0.6×	225 0.7×	114 0.5×	81 0.8×	30	716
Keisuke Kirita Japan	18	567 0.8×	471 1.3×	109 0.4×	318 1.4×	97 1.0×	57	901
Aruna Nambirajan India	17	319 0.4×	303 0.8×	147 0.5×	319 1.4×	131 1.3×	78	867
Laurie L. Carr United States	12	271 0.4×	244 0.7×	113 0.4×	186 0.8×	85 0.8×	15	810
Eisaku Miyauchi Japan	13	355 0.5×	344 0.9×	52 0.2×	239 1.0×	235 2.4×	66	691
Joeffrey Chahine United States	12	371 0.5×	92 0.3×	128 0.4×	143 0.6×	49 0.5×	26	762

Countries citing papers authored by Jacklynn V. Egger

Since Specialization

Citations

This map shows the geographic impact of Jacklynn V. Egger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacklynn V. Egger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacklynn V. Egger more than expected).

Fields of papers citing papers by Jacklynn V. Egger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacklynn V. Egger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacklynn V. Egger. The network helps show where Jacklynn V. Egger may publish in the future.

Co-authorship network of co-authors of Jacklynn V. Egger

This figure shows the co-authorship network connecting the top 25 collaborators of Jacklynn V. Egger. A scholar is included among the top collaborators of Jacklynn V. Egger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacklynn V. Egger. Jacklynn V. Egger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tringale, Kathryn R., Anna Skakodub, Jacklynn V. Egger, et al.. (2024). Prognostic Implications of Small Cell Lung Cancer Transcriptional Subtyping for CNS Metastases. JCO Precision Oncology. 8(8). e2300470–e2300470. 2 indexed citations

Marmarelis, Melina E., Xiao Wang, Leonid Roshkovan, et al.. (2023). Clinical Outcomes Associated With Pembrolizumab Monotherapy Among Adults With Diffuse Malignant Peritoneal Mesothelioma. JAMA Network Open. 6(3). e232526–e232526. 7 indexed citations

Schoenfeld, Adam J., Hira Rizvi, Danish Memon, et al.. (2022). Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical Cancer Research. 28(17). 3797–3803. 31 indexed citations

Luo, Jia, Song Wu, Hira Rizvi, et al.. (2022). Deciphering radiological stable disease to immune checkpoint inhibitors. Annals of Oncology. 33(8). 824–835. 24 indexed citations

Offin, Michael, Jennifer L. Sauter, Sam E. Tischfield, et al.. (2022). Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library. Genome Medicine. 14(1). 127–127. 3 indexed citations

Offin, Michael, Jennifer L. Sauter, Jacklynn V. Egger, et al.. (2022). Multimodality Therapy in Patients With Primary Pericardial Mesothelioma. Journal of Thoracic Oncology. 17(12). 1428–1432. 8 indexed citations

Baine, Marina K., Christopher A. Febres‐Aldana, Jason C. Chang, et al.. (2022). POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC. Journal of Thoracic Oncology. 17(9). 1109–1121. 45 indexed citations

Luo, Jia, R. Vanguri, Jacklynn V. Egger, et al.. (2022). Multimodal integration of radiology, pathology, and genomics for prediction of response to PD-1 blockade in patients with non–small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 9064–9064. 3 indexed citations

Rothwell, Dominic G., Francesca Chemi, Simon H. S. Pearce, et al.. (2022). Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers. Cancer Research. 82(12_Supplement). 6238–6238. 1 indexed citations

10.

Luo, Jia, Jason Beattie, Hira Rizvi, et al.. (2021). Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of Thoracic Oncology. 16(10). 1759–1764. 74 indexed citations

11.

Offin, Michael, Soo‐Ryum Yang, Jacklynn V. Egger, et al.. (2021). Molecular Characterization of Peritoneal Mesotheliomas. Journal of Thoracic Oncology. 17(3). 455–460. 35 indexed citations

12.

Quintanal-Villalonga, Àlvaro, Maysun Hasan, Shweta S. Chavan, et al.. (2021). 1800O Multi-omic characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. Annals of Oncology. 32. S1226–S1226. 1 indexed citations

13.

Offin, Michael, Jacklynn V. Egger, Caroline G. McCarthy, et al.. (2021). Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy.. Journal of Clinical Oncology. 39(15_suppl). 8556–8556.

14.

Zauderer, Marjorie G., Axel Martin, Jacklynn V. Egger, et al.. (2021). The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. The Lancet Digital Health. 3(9). e565–e576. 28 indexed citations

15.

Bandlamudi, Chai, Jennifer L. Sauter, William D. Travis, et al.. (2020). Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Annals of Oncology. 31(5). 599–608. 219 indexed citations

16.

Baine, Marina K., Min‐Shu Hsieh, W. Victoria Lai, et al.. (2020). SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization. Journal of Thoracic Oncology. 15(12). 1823–1835. 301 indexed citations breakdown →

17.

Luo, Jia, Chaitanya Bandlamudi, Biagio Ricciuti, et al.. (2020). Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 38(15_suppl). 9549–9549. 9 indexed citations

18.

Egger, Jacklynn V., et al.. (2016). Dephosphorylation of the Retinoblastoma protein (Rb) inhibits cancer cell EMT via Zeb. Cancer Biology & Therapy. 17(11). 1197–1205. 29 indexed citations

19.

Egger, Jacklynn V., et al.. (2014). Phosphorylation of the Retinoblastoma protein (Rb) on serine-807 is required for association with Bax. Cell Cycle. 13(22). 3611–3617. 36 indexed citations

20.

Egger, Jacklynn V., et al.. (2003). Benign sleep myoclonus in infancy mistaken for epilepsy. BMJ. 326(7396). 975–976. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact